Results 101 to 110 of about 2,826,854 (328)

Dolutegravir-Associated Hyperglycemia in a Patient on Highly Active Antiretroviral Therapies

Nigerian Journal of Medicine
Highly active antiretroviral medications have been reported to cause hyperglycaemia in the literature especially the protease inhibitor. We however report a case of dolutegravir-associated hyperglycaemia which is an integrase strand transfer inhibitor.
Abosede Grace Adeyeye, Victor Oladeji Adeyeye   +1 more
doaj   +1 more source

The mechanism of H171T resistance reveals the importance of Nδ-protonated His171 for the binding of allosteric inhibitor BI-D to HIV-1 integrase [PDF]

, 2015
Background: Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are an important new class of anti-HIV-1 agents. ALLINIs bind at the IN catalytic core domain (CCD) dimer interface occupying the principal binding pocket of its cellular cofactor LEDGF/p75.
Deng, Nanjie, Engelman, Alan, Fadel, Hind J, Feng, Lei, Fuchs, James R, Jena, Nivedita, Jurado, Kellie A, Kessl, Jacques J, Kvaratskhelia, Mamuka, Larue, Ross C, Levy, Ronald M, Patel, Pratiq A, Poeschla, Eric, Shkriabai, Nikoloz, Slaughter, Alison   +14 more
core   +1 more source

Pediatric human immunodeficiency virus infection in the modern era: A systematic review of recent advances and their implications

Pediatric Investigation, EarlyView.
This review discusses how early antiretroviral therapy initiation, long‐acting therapies, and prevention of mother‐to‐child transmission contribute to improved pediatric human immunodeficiency virus outcomes. Despite these advances, treatment complications and challenges in transitioning to adult care remain major barriers to lifelong management ...
Klaudia Nowak, Krzysztof Łupina, Dominika Lorek, Aleksandra Jabłońska, Alicja Radomska, Tymon Choromański, Jakub Janczura   +6 more
wiley   +1 more source

Brief Histories of Retroviral Integration Research and Associated International Conferences

Viruses
The field of retroviral integration research has a long history that started with the provirus hypothesis and subsequent discoveries of the retroviral reverse transcriptase and integrase enzymes.
Duane P. Grandgenett, Alan N. Engelman
doaj   +1 more source

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

mBio, 2017
Resistance to the integrase strand transfer inhibitors raltegravir and elvitegravir is often due to well-identified mutations in the integrase gene. However, the situation is less clear for patients who fail dolutegravir treatment.
Isabelle Malet, Frédéric Subra, Charlotte Charpentier, Gilles Collin, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin, Olivier Delelis   +7 more
doaj   +1 more source

Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation [PDF]

, 2017
Current antiretroviral therapy (ART) for HIV/AIDS slows disease progression by reducing viral loads and increasing CD4 counts. Yet ART is not curative due to the persistence of CD4+ T-cell proviral reservoirs that chronically resupply active virus ...
Albert, Brice J, Barnes, Alexander B, Kyei, George B, Marshall, Garland R, Niu, Austin, Ramani, Rashmi, Ratner, Lee, Wender, Paul A, Williams, Robert M   +8 more
core   +2 more sources

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

Antimicrobial Agents and Chemotherapy, 2016
Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory concentration [IC50] of 7.5 ± 0.3 nM) and HIV-1 integration in cells.
M. Tsiang, Gregg S. Jones, J. Goldsmith, Andrew Mulato, Derek Hansen, E. Kan, Luong K. Tsai, Rujuta A. Bam, G. Stepan, Kirsten M. Stray, A. Niedziela-Majka, S. Yant, Helen Yu, G. Kukolj, T. Cihlář, Scott E. Lazerwith, K. White, Haolun Jin   +17 more
semanticscholar   +1 more source

Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing

Small, EarlyView.
The review highlights nature‐inspired nanocarriers for CRISPR delivery, emphasizing viral vectors, extracellular vesicles, liposomes, and lipid nanoparticles. It discusses their roles in improving specificity, minimizing immunogenicity, and overcoming barriers in genome editing. Recent advancements, challenges, and therapeutic applications are explored,
Elizabeth Maria Clarissa, Mamata Karmacharya, Hyunmin Choi, Sumit Kumar, Yoon‐Kyoung Cho   +4 more
wiley   +1 more source

Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth

Nature Communications, 2022
Neonates and infants infected with HIV generally develop disease rapidly, with early antiretroviral therapy (ART) often failing to achieve a sustained state of ART-free virologic remission.
Xiaolei Wang, Eunice Vincent, Summer Siddiqui, Katherine Turnbull, Hong Lu, Robert Blair, Xueling Wu, Meagan Watkins, Widade Ziani, Jiasheng Shao, Lara A. Doyle-Meyers, Kasi E. Russell-Lodrigue, Rudolf P. Bohm, Ronald S. Veazey, Huanbin Xu   +14 more
doaj   +1 more source

CRISPR/Cas9‐edited tumor‐associated immune cells in cancer immunotherapy

VIEW, EarlyView.
Abstract Immuno‐oncology represents an emerging field that has significantly transformed tumor therapeutics, with immune cells serving as the cellular foundations of cancer immunotherapy. Due to its high efficiency and sensitivity, CRISPR/Cas9 genome editing is a highly promising technique for precise and rapid gene modification.
Yuhui Ma, Junxin Chen, Yuan Du, Zhihao Cao, Weizhi Ji, Yuyu Niu, Zebin Yang   +6 more
wiley   +1 more source